Artiva Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARTV Nasdaq 2836 www.artivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artiva Biotherapeutics, Inc.

Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Dec 14th, 2025 4:05 am
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - Nov 12th, 2025 5:20 am
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Nov 12th, 2025 5:00 am
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® - Nov 3rd, 2025 2:05 pm
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November - Oct 30th, 2025 2:17 pm
3 Promising Penny Stocks With Market Caps Under $200M - Oct 29th, 2025 12:04 pm
Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101) - Oct 22nd, 2025 5:41 am
Artiva Biotherapeutics (ARTV): Valuation Snapshot Following FDA Fast Track for AlloNK in Refractory Rheumatoid Arthritis - Oct 20th, 2025 6:05 am
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? - Oct 19th, 2025 5:11 am
Top Midday Gainers - Oct 17th, 2025 11:58 am
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update - Oct 16th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Over $90M - Sep 26th, 2025 6:04 am
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 - Aug 25th, 2025 2:05 pm
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights - Aug 6th, 2025 2:05 pm
Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely? - Jun 29th, 2025 6:08 am
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference - May 28th, 2025 2:05 pm
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - May 13th, 2025 2:05 pm
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights - May 8th, 2025 6:00 am
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting - Apr 28th, 2025 2:35 pm
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Apr 8th, 2025 2:05 pm